## WST: West Pharmaceutical Services, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.2% below STRENGTH zone (3.0-6.0%); PEG 3.39 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($259.43)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Texas Permanent School Fund Corp Has $2.44 Million Stock Holdings in West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20251221T102125 | Bullish | Relevance: 100%
- Texas Permanent School Fund Corp significantly reduced its stake in West Pharmaceutical Services (NYSE:WST) by 47.9% in Q2, selling over 10,000 shares but still retaining holdings valued at $2.439 million. Analysts maintain a "Moderate Buy" consensus for WST with an average price target of $342.20, following strong Q3 earnings where the company beat EPS and revenue estimates, and announced a quarterly dividend. Other institutional investors have shown mixed activity, with some increasing and others initiating positions in the medical instruments supplier.

**2. Riverbridge Partners LLC Cuts Stock Position in West Pharmaceutical Services, Inc. $WST**
- Source: MarketBeat | 20251222T130207 | Somewhat-Bullish | Relevance: 100%
- Riverbridge Partners LLC reduced its stake in West Pharmaceutical Services (NYSE:WST) by 5.5% in Q3, now holding 362,540 shares valued at $95.1 million. West Pharmaceutical Services reported strong Q3 earnings, beating estimates with $1.96 EPS and $804.6 million in revenue, and issued optimistic FY2025 guidance. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $342.20.

**3. West Pharmaceutical Services (NYSE:WST) Stock Rating Upgraded by Wall Street Zen**
- Source: MarketBeat | 20251220T070823 | Bullish | Relevance: 100%
- Wall Street Zen has upgraded West Pharmaceutical Services (NYSE:WST) from a "hold" to a "buy" rating, aligning with other analysts who maintain a "Moderate Buy" consensus and an average price target of $342.20. The upgrade follows strong quarterly results, where West exceeded EPS and revenue expectations and provided optimistic FY2025 guidance. The company’s stock performance shows a 12-month trading range of $187.43–$348.90, with institutional investors holding a significant portion of its shares.

**4. West Pharmaceutical Services, Inc. $WST Position Decreased by Seilern Investment Management Ltd**
- Source: MarketBeat | 20251222T110945 | Somewhat-Bullish | Relevance: 96%
- Seilern Investment Management Ltd significantly reduced its stake in West Pharmaceutical Services (NYSE:WST) by 24.2% in Q3, selling over 104,000 shares. Despite this, West Pharmaceutical reported strong Q3 earnings, beating analyst estimates with an EPS of $1.96 and revenue of $804.6 million, and issued positive FY2025 guidance. Analysts maintain a "Moderate Buy" consensus with an average target price of $342.20, following several recent upgrades.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $285 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($0.14M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Vanguard Group Inc: 13.5% (+4.2%)
- Blackrock Inc.: 9.0% (-2.3%)
- State Street Corpora: 4.5% (-1.9%)
- Bank Of New York Mel: 4.0% (-9.4%)
- Artisan Partners Lim: 3.9% (+22.2%)

### Key Risks

1. Valuation stretched: PEG 3.4x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +2.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.39 signals overvaluation risk, limited margin of safety. Forward P/E 35.3x stretched relative to 10% growth. Quality metrics strong (ROA 10%, margin 16%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.35). Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $19.8B |
| Beta | 1.17 |
| 52W Range | $187.43 - $348.90 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.39 |
| Forward P/E | 35.3 |
| Current P/E | 38.7 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.0% to 1.2% (+2.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.8pp (needs >3.0% for momentum thesis). MRS_5 at 0.3% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 53. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.19% (CS: 72) | Neutral |
| RSI_14 | 52.9 | Neutral |
| MACD Histogram | 0.07 | Bullish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 1.003x | Above |
| vs SMA200 | 1.138x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $274.87
- **Stop Loss:** $259.43 (5.6% risk)
- **Target:** $290.31 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 77
- **Position Value:** $21,164.99
- **Portfolio %:** 21.16%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-12 (Est: $1.83)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.71 | $1.96 | +14.5% |
| 2025Q2 | $1.54 | $1.84 | +19.7% |
| 2025Q1 | $1.26 | $1.45 | +15.3% |
| 2024Q4 | $1.73 | $1.82 | +5.3% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*